Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKEEGA vs AFATINIB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.
Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.
Treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (m CRPC) in combination with prednisone.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy,Off-label: Use in other EGFR-mutant cancers (e.g., head and neck cancer, colorectal cancer) with specific mutations
Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.
40 mg orally once daily, continuously.
Terminal half-life: 17–30 hours (mean ~24 h); allows once-daily dosing but may require dose adjustment in renal impairment.
Terminal half-life is approximately 37 hours; supports once-daily dosing with steady-state achieved within 8 days.
Niraparib is primarily metabolized by carboxylesterases (CEs) and to a lesser extent by CYP1A2 and CYP2D6. Abiraterone acetate is hydrolyzed to abiraterone, which is then metabolized by CYP3A4 and CYP2D6.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP3A4-independent pathways including flavin-containing monooxygenase (FMO). Excretion mainly via feces (85%) and urine (4%) as unchanged drug and metabolites.
Renal: ~85% (primarily as unchanged drug); Biliary/Fecal: ~15%.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <4% of the dose.
~99% (bound primarily to α1-acid glycoprotein and albumin).
Approximately 95% bound to plasma proteins, primarily to albumin.
Vd: ~1.5–2.0 L/kg (indicates extensive tissue distribution).
Volume of distribution is approximately 2300 L (about 33 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Oral: ~90% (high oral bioavailability).
Oral bioavailability is approximately 92% relative to an oral solution; food reduces exposure, so take on an empty stomach.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Not recommended for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
No starting dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to safety concerns.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; but monitor closely for toxicity.
Child-Pugh A: 40 mg once daily. Child-Pugh B: Reduce dose to 30 mg once daily. Child-Pugh C: Not recommended due to lack of data.
Safety and efficacy not established in pediatric patients; no recommended dose.
Safety and efficacy not established in pediatric patients; no specific dosing recommendations.
No specific dose adjustment required. Clinical studies included patients ≥65 years; increased risk of adverse effects such as hypertension, hypokalemia, and fatigue. Monitor renal function and electrolytes regularly.
No specific dose adjustment recommended based on age alone; monitor renal function and tolerability, as elderly patients may have decreased renal function or comorbidities.
AKEEGA can cause severe and persistent hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, especially in patients with renal impairment. Monitor blood pressure, serum potassium, and fluid status regularly.
None.
Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess,Adrenocortical insufficiency,Hepatotoxicity,Cardiovascular effects including QT prolongation,Bone marrow suppression (anemia, thrombocytopenia, neutropenia),Fetal harm if used during pregnancy
Severe diarrhea (including dehydration and acute kidney injury),Interstitial lung disease (ILD)/pneumonitis,Severe hepatotoxicity (elevated liver enzymes, hepatitis),Left ventricular dysfunction (assess LVEF at baseline and during treatment),Severe bullous, blistering, and exfoliative skin reactions (e.g., Stevens-Johnson syndrome),Gastrointestinal perforation,Ocular toxicities (keratitis, conjunctivitis),Renal toxicity (proteinuria, nephrotic syndrome),Fetal harm (embryo-fetal toxicity),Drug interactions with CYP3A4 inducers or inhibitors
Concomitant use with strong CYP3A4 inducers,Severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease,History of hypersensitivity to niraparib, abiraterone, or any excipient
None reported,Relative contraindications: pre-existing severe hepatic impairment, severe renal impairment, pregnancy, and breastfeeding
Avoid food and beverages containing grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and may increase abiraterone exposure. Take AKEEGA on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid high-fat meals as they increase abiraterone absorption.
Take on an empty stomach (at least 1 hour before or 2 hours after food). Avoid grapefruit, grapefruit juice, and Seville oranges as they may alter drug metabolism. High-fat meals reduce absorption.
AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abiraterone acetate is also associated with fetal risks. First trimester exposure may cause embryofetal lethality and teratogenicity. Second and third trimester exposure may impair fetal adrenal function and androgen-dependent development.
Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neural tube defects based on animal studies showing embryotoxicity and teratogenicity at doses below human exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and impaired renal function due to inhibition of EGFR signaling critical for fetal development.
No data on the presence of niraparib or abiraterone in human milk, effects on breastfed infants, or milk production. Due to the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio is unknown.
No human data on afatinib excretion in breast milk; however, animal studies indicate drug presence in milk. M/P ratio is unknown. Due to potential for serious adverse effects in breastfed infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after the last dose.
No specific dose adjustments are established during pregnancy as AKEEGA is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate dose adjustments if used inadvertently, but no data are available. If exposure occurs, cautious monitoring and individualized dosing are recommended.
No specific dosing guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may occur but studies have not established dose adjustments. The drug should be avoided in pregnancy unless benefit outweighs risk; if used, consider therapeutic drug monitoring if available.
AKEEGA (niraparib and abiraterone acetate) is indicated for BRCA-positive metastatic castration-resistant prostate cancer. Monitor for myelosuppression (CBC at baseline and monthly), hypertension (BP weekly for first month then monthly), hypokalemia, and hepatotoxicity (LFTs at baseline and monthly). CYP3A4 inhibitors increase abiraterone exposure; avoid strong inhibitors or reduce dose. Corticosteroid co-administration (prednisone 5 mg BID) is required to manage mineralocorticoid excess. Niraparib may cause fetal harm; confirm pregnancy status before initiation.
Monitor for diarrhea, which can be severe; consider loperamide and hydration. Assess for interstitial lung disease (ILD) and hepatotoxicity. Dose reduction required for severe renal impairment (Cr Cl 15–29 m L/min). For patients with EGFR exon 19 deletion or exon 21 L858R mutation, first-line use improves PFS. Avoid P-glycoprotein strong inducers (e.g., rifampin) during treatment.
Take tablets on an empty stomach, at least 1 hour before or 2 hours after a meal.,Swallow tablets whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment.,Use effective contraception during treatment and for 4 months after the last dose for females and 3 months for males.,Report signs of bone marrow suppression: fever, bruising, bleeding, or unusual tiredness.,Report symptoms of high blood pressure: severe headache, blurred vision, or chest pain.,Take prednisone exactly as prescribed; do not stop abruptly.,Avoid pregnancy; discuss fertility preservation options before starting treatment.,Take missed doses if within 12 hours of scheduled time; otherwise skip and resume next day.,Store at room temperature; keep in original container.
Take afatinib at least 1 hour before or 2 hours after a meal.,Do not crush, chew, or split tablets; swallow whole with water.,Seek medical help for severe or persistent diarrhea, cough, or difficulty breathing.,Avoid grapefruit and Seville oranges during treatment.,Report signs of liver problems (yellowing skin/eyes, dark urine).,Use effective contraception during and for 2 weeks after stopping therapy.,Avoid direct sunlight exposure; use sunscreen.
No interactions on record
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
"The combination of afatinib, a tyrosine kinase inhibitor, with pantoprazole, a proton pump inhibitor (PPI), can lead to reduced absorption of afatinib due to elevated gastric pH. Afatinib exhibits pH-dependent solubility, and higher gastric pH decreases its dissolution and bioavailability, potentially reducing its therapeutic efficacy. This interaction may result in suboptimal plasma concentrations of afatinib, increasing the risk of treatment failure in patients with non-small cell lung cancer."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKEEGA vs AFATINIB, answered by our medical review team.
AKEEGA is a Antineoplastic Combination that works by Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.. AFATINIB is a Tyrosine Kinase Inhibitor Antineoplastic that works by Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKEEGA and AFATINIB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKEEGA is: Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.. The standard adult dose of AFATINIB is: 40 mg orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKEEGA and AFATINIB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKEEGA is classified as Category C. AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abirate. AFATINIB is classified as Category C. Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neura. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.